Delayed-onset cardiotoxicity of anthracyclines is associated with dysregulation of FOXK1 targets
Clicks: 9
ID: 323470
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
2.4
/100
9 views
8 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #163 of 291 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 291 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Anthracyclines remain one of the most used chemotherapeutic agents in the treatment of various cancers. Despite the highly efficient anti-tumor activity, the use is limited by the associated cardiotoxicity. A subset of patients that receive anthracyclines present with dilatative cardiomyopathy several years after their initial exposition. The precise mechanisms underlying this delayed maladaptive response remains poorly understood. Purpose The purpose of this study was to gain a better understanding of the delayed maladaptive cardiac response to anthracyclines and thuswe hypothesized that an exposure to anthracyclines increases cardiac susceptible to future adverse stress response. Methods To test this, a ‘two-hit’ model using neonatal rat cardiomyocytes was developed. Cells treated with low doses of doxorubicin (Doxo) for 1 h followed by beta-adrenergic stimulation using Isoproterenol (Iso), five days later. A similar 'two-hit' model using a combination of Doxo+Iso was applied to a mouse model where C57B6 mice received doxorubicin and isoproterenol with a gap of two months. Results Neonatal rat cardiomyocytes treated with low doses of doxorubicin for 1 h followed by beta-adrenergic stimulation using Isoproterenol (Iso), five days later. Even after a five-day gap between the initial exposure to doxorubicin and isoproterenol, an increased expression of the pathological marker Nppb was observed, suggesting the presence of a memory of anthracycline exposure by the cardiomyocytes (Iso, fc=2.79; Doxo+Iso, fc=5.5 vs. control, p= 0.0241, <0.0001). The in vivo study revealed that mice receiving a combination of Doxo+Iso with a gap of two months between the two treatments had significantly worse heart function compared to mice receiving either Doxo or Iso alone. RNA-seq led to the identification of FOXK1 as a potential transcriptional factor upstream of a maladaptive gene program regulated by Doxo+Iso compared to Doxo alone. In addition, ATAC-seq of mitochondria isolated from hearts of mice unraveled a previously unrecognized regulatory region in the MT-RNR2 gene with reduced DNA accessibility upon doxorubicin exposure. An unbiased in vitro proteomic-interaction screen of this region again identified FOXK1 as an interacting protein, suggesting a role in direct regulation of mitochondrial function. Conclusion Ongoing studies employing a cardiomyocyte-specific, conditional FOXK1 knockout mouse models and targeted overexpression of FOXK1 in primary cells will aim to further elucidate the mechanistic role of FOXK1 in the long-term anthracycline toxicity. Collectively, our findings identify FOXK1 as a novel mediator of long-term anthracycline-induced cardiac mitochondrial dysfunction, acting through both nuclear transcriptional control and direct regulation of mitochondrial gene accessibility.
| Reference Key |
openalex_W7172286538
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | V Sunder, B Eksi, D Finke, J Brauer, N Frey, L H Lehmann |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.228
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.